Boehringer Ingelheim cuts around 50 jobs in Vienna

The company confirmed a report by "Falter" (online) upon APA's request. Due to lower customer demand, components for a specific cancer vaccine will no longer be produced.

Boehringer Ingelheim is now seeking a successor project to "continue to utilize the capacities in the best possible way." The production stop affects around 150 of the 1,800 employees in Boehringer Ingelheim's Austrian biopharmaceutical division. The pharmaceutical company intends to continue employing about half of the affected employees in other areas at the Vienna site. For those employees who cannot be retained despite internal offers, a social plan and "comprehensive support measures have been agreed" together with the works council, the company stated.

Boehringer Ingelheim employs around 3,500 people in Vienna

The Boehringer Ingelheim Regional Center Vienna (RCV) in the 12th district of Vienna has around 3,500 employees. The total number of employees at the Vienna site will "not change significantly" year-on-year, the pharmaceutical company explained to the APA. The production facilities are "still well utilized" and the discontinuation of the vaccine project has "no significant impact" on business success. "The 2025 fiscal year is proceeding very satisfactorily with growth in all business areas," the company said.

Boehringer Ingelheim invests, according to its own statements, 30 to 50 million euros annually in the infrastructure at the Vienna site. Additionally, a new office building for 1,000 employees is currently being constructed with an investment volume of around 100 million euros.

(APA/Red)

This article has been automatically translated, read the original article here.